2Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1993, 243:290-293.
3Fenk R, Ak M, Kobbe G, et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica, 2004, 89: 557-566.
4Kim YJ, Kim DW, Lee S. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective;randomized trial. Bone Marrow Transplant, 2004, 33:535-542.
5Hagop MK, Moshe T, Jorge C, et al. Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia. Clin Cancer Res, 2003, 9: 160-166.
6Kluin-Nelemans HC, Buck G, le Cessie S, et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood, 2004, 103: 4408-4415.
7Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med, 1997, 337: 223-229.
8Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood, 2001, 98: 3074-3081.
9Baccarani M, Rosti G, De Vivo A, et al. A randomized study of interferon alpha versus interferon alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 2002, 99: 1527-1535.
10Hehlmann R, Berger U, Pirrmann M, et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia, 2003, 17: 1529-1537.
